PancreaSure
Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Individuals
Commercial PreparationActive
Key Facts
Indication
Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Individuals
Phase
Commercial Preparation
Status
Active
Company
About Immunovia
Immunovia is a lean, focused diagnostics company dedicated to improving the abysmal survival rate of pancreatic cancer through early detection. Its core achievement is the development of PancreaSure, a blood test demonstrating 78% sensitivity and 94% specificity for early-stage disease in validation studies. The company's strategy is to execute a capital-efficient commercial launch in the U.S. in late 2025, targeting the significant unmet need in surveillance for high-risk populations, thereby aiming to create substantial shareholder value.
View full company profile